Concord Biotech Limited (BOM:543960)

Market Cap	216.66B
Revenue (ttm)	12.00B
Net Income (ttm)	3.72B
Shares Out	n/a
EPS (ttm)	35.52
PE Ratio	58.30
Forward PE	47.85
Dividend	8.75 (0.43%)
Ex-Dividend Date	Jun 21, 2024

Volume	30,433
Average Volume	13,169
Open	1,931.05
Previous Close	1,927.25
Day's Range	1,917.35 - 2,058.25
52-Week Range	1,370.05 - 2,658.00
Beta	n/a
RSI	71.64
Earnings Date	May 23, 2025

About Concord Biotech

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, ...

• Industry: Pharmaceutical Preparations
• Founded: 1984
• Employees: 1,377
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 543960

Financial Performance

In 2024, Concord Biotech's revenue was 12.00 billion, an increase of 18.01% compared to the previous year's 10.17 billion. Earnings were 3.72 billion, an increase of 20.62%.